Global Oral Proteins and Peptides Market Report and Forecast 2024-2032

Global Oral Proteins and Peptides Market Outlook

The global oral proteins and peptides market size was valued at USD 2.5 billion in 2023, driven by the growing biotechnological and pharmaceutical advancements across the globe. The market is expected to grow at a CAGR of 14.5% during the forecast period of 2024-2032, with the values likely to rise from USD 2.8 billion in 2024 to USD 8.3 billion by 2032.

Global Oral Proteins and Peptides Market Overview

Oral proteins and peptides involve the administration of large biomolecules orally, usually in the form of capsules, pills, or liquid formulations. Oral delivery is commonly preferred over the intravenous methods as it offers a patient friendly and painless option. The non-invasive nature of oral route of drug administration leads to improved quality of life, especially for those requiring long-term or chronic treatment. It may also facilitate fewer visits to the healthcare facilities and a minimized risk of infection. Such factors have led to increased oral proteins and peptides market demand in recent years.

Increasing Burden of Chronic Diseases to be the Key Growth Driver

Oral insulin is a key area of research owing to the rising prevalence of diabetes. Currently, approximately half a billion people are living with diabetes worldwide and the incidence is expected to rise to double and reach 1.3 billion in the next 30 years . Therefore, oral proteins and peptides can be considered as a convenient way to offer improved and effective solutions for the patients suffering from the disease. They are also being investigated to treat other conditions such as osteoporosis, cancer, inflammatory bowel disease, and autoimmune diseases and the growing prevalence of such diseases is anticipated to boost the oral peptides and proteins market growth in the forecast period.

Surge in Technical Advancements to Develop New Drugs

With increasing advancements in biotechnology as well as gene technology, designing oral peptides has also become comparatively easier. Researchers can now combat the constraints of oral peptide and protein delivery systems which include unfavourable physicochemical properties such as large molecular size, along with the tendency to undergo enzymatic degradation, aggregation, adsorption, and denaturation. Such technical innovations are expected to boost the oral proteins and peptides market size. In January 2023, the scholars at Uppsala University constructed a new machine for protein separation. The new method helps in capillary electrophoresis  (which helps in molecular segregation based on different charges) in a cost-effective manner.

Expediated Drug Development to Address Multiple Diseases

In November 2023, Entera Bio Ltd.,  an oral peptide company, revealed development on five new oral peptides programs. There is development on the first Osteoporosis oral and osteoanabolic drug, called EB613. The company partnered with the American Society for Bone and Mineral Research (ASBMR) to submit the drug for FDA approval. The oral proteins and peptide market share is anticipated to grow with increased number of drugs under pipeline for multiple diseases. EB613 for intense sports and military stress injuries, EB612 for hypoparathyroidism, GLP-2 peptide tablets for short bowel syndrome, and GLP-1 peptides for obesity are some of the prominent examples of drugs under a pipeline.

Development of New Devices to Facilitate Oral Route of Administration

In September 2023, Biora Therapeutics, Inc.,  revealed their company’s latest invention, a BioJet™ platform for oral and systemic delivery of biotherapeutics. The platform uses an ingestible capsule, approximately like the size of a multivitamin and designed to transit through the digestive system and get activated in the small intestine. It can be used to deliver a wide of molecules including proteins, nucleic acids, and peptides in liquid formulations up to 400µL. It is an effective needle free route of delivering large molecules and is expected to replace injections for better management of chronic diseases.

Global Oral Proteins and Peptides Market Segmentation

Market Breakup by Drug Type

• Plecanatide

• Linaclotide

• Octreotide

• Calcitonin

• Insulin

Market Breakup by Application

• Gastric and Digestive Disorders

• Bone Diseases

• Diabetes

• Hormonal Disorders

Market Breakup by End User

• Hospitals

• Ambulatory Surgical Centre

• Clinics

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Global Oral Proteins and Peptides Market Regional Analysis

North America, led by the United States and Canada, is expected to lead the oral proteins and peptides market share in the forecast period. The market size can be accredited to a robust biotech along with research and development infrastructure. The existence of proactive regulatory authorities like the FDA also ensures the drug efficacy and contributes to the growth of the market.

With the presence of key academic institutions and pharmaceutical companies, Europe is another major market for oral proteins and peptides. The rising partnerships between the public and private entities is also garnering developments in the drug markets. The high prevalence of diseases such as diabetes and other bone related issues in the geriatric population also pushes innovation for improved patient alternatives.

Asia Pacific is expected to witness the oral proteins and peptides market growth attributed to rising investment in improving the research and development infrastructure. Moreover, the increasing influx of foreign capital is a major aspect of the market growth.

Global Oral Proteins and Peptides Market: Competitor Landscape

In September 2023, Entera Bio Ltd.  partnered with OPKO Health, Inc., under a research agreement to expand their oral delivery technology across two extra peptides, namely GLP-2 for the treatment of short bowel syndrome, and Oxyntomodulin (OXM), a dual targeted GLP-1/glucagon agonist for treating obesity. Under the terms of the agreement, the companies will be responsible for specific phases of development leveraging their area of expertise.

The key features of the oral proteins and peptides market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Novo Nordisk A/S

• Synergy Pharmaceuticals Inc.

• Chiasma Inc.

• Tarsa Therapeutics Inc.

• Biocon Limited

• Generex Biotechnology Corp.

• AstraZeneca PLC

• Proxima Concepts Limited

• Oramed Pharmaceuticals Inc.

• Allergan Plc.

• Generex Biotechnology Corp.

• Hoffmann-La Roche

• Sanofi

• Bristol-Myers Squibb Company

• Hovione

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report